Developed through a collaboration between Accenture and Oracle, the INTIENT Clinical platform will help Bayer simplify and accelerate its drug development processes.
Accenture Life Sciences practice managing director Mike Stapleton said: “We are excited to work with Bayer to provide new insights on their clinical trials so they can bring the important treatments they develop to patients faster and with the highest quality.
“The future of R&D is bright when leading organisations come together to solve for patients’ greatest needs.”
By combining internal and external clinical data with Oracle Cloud-based technologies into a single data management and warehousing solution, the INTIENT Clinical platform is set to create new insights to accelerate drug development and improve patient outcomes.
The platform supports the delivery of patient treatments by integrating new technology, advanced analytics and applied intelligence.
It also combines the implementation experience of Accenture with solutions such as the Oracle Health Sciences Data Management Workbench and Oracle Life Sciences Data Hub.
These solutions together generate quality data from clinical trials and reduce the time, effort, and cost needed to take drugs from development to market.
Powered by Oracle Cloud Infrastructure, the Oracle solutions are supported with Oracle Managed Cloud Services.
Bayer has also joined the Life Sciences Cloud Coalition, which seeks to enable pre-competitive collaboration between pharmaceutical companies to advance clinical development.
Oracle Health Sciences senior vice-president and general manager Steve Rosenberg said: “We welcome Bayer as a new member of the Life Sciences Cloud Coalition and to the Oracle Health Sciences Data Management Workbench family.
“Their perspective and experience will be invaluable in the advancement of clinical development for the entire industry.”